Essity AB (publ) (ETTYF) Q2 2026 Earnings Call Transcript

Essity reported positive organic sales growth in Q2 2026, driven by solid volume trends and improved value propositions from higher marketing investment and selective price adjustments. Growth was seen in 3 of 4 business units (Health & Medical, Personal Care, Professional Hygiene), while Consumer Tissue was weaker. Profitability/margins remained healthy but were slightly negatively impacted by the geopolitical environment.

Analysis

Essity’s read-through is less about a single quarter and more about proof that the company can still buy share without destroying pricing. That matters because in hygiene/staples, volume recovery plus selective price actions usually signals the brand stack is strong enough to offset private-label pressure; the likely losers are weaker tissue competitors and retailers leaning on own-label penetration. The more durable franchises are Health & Medical and Professional Hygiene, where contract stickiness and replenishment demand should support a cleaner earnings path than consumer tissue.

The margin detail is the key second-order item: the geopolitical drag is probably an input/logistics issue, not a demand issue, which means it can reverse faster than the market expects if energy, freight, or sourcing normalizes. If that happens, incremental volume should flow through at a high rate over the next 1-3 quarters, especially because the company appears to be spending behind the business rather than chasing top-line with discounting. Over 6-18 months, the mix shift toward higher-quality categories can justify a small multiple rerating versus slower-moving staples peers.

The contrarian risk is that consumer tissue weakness is an early warning of broader trade-down behavior, and that the current ‘healthy margins’ framing is masking a category split that becomes more visible once pricing lags volume. If tissue remains weak into the next print or if margin recovery fails despite stable inputs, the market will likely fade the thesis quickly. This is a good setup for a modest, not aggressive, long: the signal is positive, but not strong enough to ignore category cyclicality.

Key Decisions for Investors

• Buy ETTYF on any 3-5% post-print pullback; 3-6 month hold, targeting mid-single-digit upside if volume leadership persists and margin normalization starts to show through.
• Pair trade: long ETTYF / short KMB for 3-6 months to express relative mix quality and pricing discipline in hygiene versus a more mature tissue-heavy peer; cut the trade if ETTYF consumer tissue deterioration widens.
• Set a watch item on the next quarterly margin bridge: if geopolitical cost pressure does not reverse and operating margin fails to improve, reduce the long by half.